LEUCINE AND NICOTINIC ACID REDUCES LIPID LEVELS
First Claim
Patent Images
1. A composition comprising:
- a. at least about 250 mg of leucine and/or at least about 25 mg of one or more leucine metabolites; and
b. at least about 1 mg of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.
-
Citations
102 Claims
-
1. A composition comprising:
-
a. at least about 250 mg of leucine and/or at least about 25 mg of one or more leucine metabolites; and b. at least about 1 mg of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
-
-
39. A composition comprising:
-
a. at least about 250 mg of leucine and/or at least about 25 mg of one or more leucine metabolites; and b. an amount of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites, wherein the composition is substantially free of each of alanine, glycine, glutamic acid, and proline. - View Dependent Claims (45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)
-
-
40. A composition comprising:
-
a. at least about 250 mg of leucine and/or about at least 25 mg of one or more leucine metabolites; and b. an amount of nicotinic acid and/or nicotinamide riboside and/or nicotinic acid metabolites, wherein the amount of nicotinic acid and/or nicotinic acid metabolites is insufficient to reduce lipid content in the absence of component (a).
-
-
41. A composition comprising:
-
a. an amount of leucine and/or one or more leucine metabolites; and b. an amount of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites, wherein the composition is administered to a subject in need thereof, further wherein the composition causes a reduced degree of cutaneous vasodilation in the subject administered as compared to a dose of nicotinic acid alone that has the same effectiveness as the composition in lowering lipid content in the subject. - View Dependent Claims (43, 44)
-
-
42. A composition comprising:
-
a. leucine and/or one or more leucine metabolites; and b. at least about 1 mg of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites, wherein the molar ratio of component (a) to (b) in said composition is greater than about 20.
-
- 82. A method of lowering total cholesterol level in a subject in need thereof, comprising administering to said subject a dose of a composition comprising leucine and/or one or more leucine metabolites and an amount of nicotinic acid and/or nicotinic acid metabolites to effect the total cholesterol level in the subject.
- 88. A method of reducing a side effect of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites wherein the side effect is characterized by an increase in cutaneous vasodilation in a subject administered with nicotinic acid and/or nicotinamide riboside and/or the one or more nicotinic acid metabolites, comprising administering a composition comprising an effective amount of leucine and/or one or more leucine metabolites to said subject that is administered with nicotinic acid and/or the one or more nicotinic acid metabolites.
- 97. A method of reducing atherosclerotic plaque size in a subject in need thereof, comprising administering to said subject a dose of a composition comprising leucine and/or one or more leucine metabolites and an amount of nicotinic acid and/or nicotinic acid metabolites to effect the total atherosclerotic plaque size in the subject.
Specification